Iron accumulation in lung allografts is associated with acute rejection but not with adverse outcome

Chest

Volumn 128, Issue 3, 2005, Pages 1379-1384

  Sandmeier, Petra ^a   Speich, Rudolf ^a   Grebski, Elzbieta ^a   Vogt, Peter ^a   Russi, Erich W ^a   Weder, Walter ^a   Boehler, Annette ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

BAL; Bronchiolitis obliterans syndrome; Iron metabolism; Lung transplantation; Transbronchial lung biopsy

Indexed keywords

HEMOSIDERIN; IRON;

ACUTE GRAFT REJECTION; ARTICLE; BRONCHIOLITIS OBLITERANS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ERYTHROCYTE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; LUNG FIBROSIS; LUNG LAVAGE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; RISK FACTOR; TRANSBRONCHIAL BIOPSY;

EID: 24944485005     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1379     Document Type: Article

References (23)

1. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002; 166:440-444
2. Boehler A, Kesten S, Weder W, et al. Bronchiolitis obliterans after lung transplantation: a review. Chest 1998; 114:1411-1426
3. McKane BW, Trulock EP, Patterson GA, et al. Lung transplantation and bronchiolitis obliterans: an evolution in understanding. Immunol Res 2001; 24:177-190
4. Scott JP, Higenbottam TW, Sharples L, et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation 1991; 51:813-817
5. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110:4-13
6. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15:1200-1208
7. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17:1255-1263
8. Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients: an analysis of 200 consecutive procedures. Chest 1992; 102:1049-1054
9. Boehler A, Vogt P, Zollinger A, et al. Prospective study of the value of transbronchial lung biopsy after lung transplantation. Eur Respir J 1996; 9:658-662
10. Swanson SJ, Mentzer SJ, Reilly JJ, et al. Surveillance transbronchial lung biopsies: implication for survival after lung transplantation. J Thorac Cardiovasc Surg 2000; 119:27-37
11. Clelland CA, Higenbottam TW, Stewart S, et al. The histological changes in transbronchial biopsy after treatment of acute lung rejection in heart-lung transplants. J Pathol 1990; 161:105-112
12. Baz MA, Ghio AJ, Roggli VL, et al. Iron accumulation in lung allografts after transplantation. Chest 1997; 112:435-439
13. Reid D, Snell G, Ward C, et al. Iron overload and nitric oxide-derived oxidative stress following lung transplantation. J Heart Lung Transplant 2001; 20:840-849
14. Speich R, Boehler A, Zalunardo M, et al. Improved results after lung transplantation - analysis of factors. Swiss Med Wkly 2001; 131:238-245
15. Speich R, Thurnheer R, Gaspert A, et al. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999; 67:315-320
16. Grebski E, Russi EW, Hess T, et al. Diagnostic value of hemosiderin-containing macrophages in bronchoalveolar lavage. Chest 1992; 102:1794-1799
17. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996; 15:1-15
18. Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124:1232-1241
19. Egan JJ, Lomax J, Barber L, et al. Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 1998; 65:747-752
20. International Society for Heart and Lung Transplantation. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12:713-716
21. De Lassence A, Fleury-Feith J, Escudier E, et al. Alveolar hemorrhage: diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 1995; 151:157-163
22. Egan JJ, Martin N, Hasleton PS, et al. Pulmonary interstitial fibrosis and haemosiderin-laden macrophages: late following heart transplantation. Respir Med 1996; 90:547-551
23. Sherman JM, Winnie G, Thomassen MJ, et al. Time course of hemosiderin production and clearance by human pulmonary macrophages. Chest 1984; 86:409-411